Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients

Morgan Hakki, James S. Lewis

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Multidrug-resistant (MDR) Pseudomonas aeruginosa infection causes significant mortality among patients with hematologic malignancies and hematopoietic-cell transplant recipients. Ceftolozane-tazobactam (C-T) is a novel therapeutic option for MDR-P. aeruginosa infections but clinical experience in these patients is limited. We report favorable clinical outcomes and lack of limiting toxicities using C-T monotherapy to treat invasive MDR-P. aeruginosa infections in these patient populations.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalInfection
DOIs
StateAccepted/In press - Feb 19 2018

Fingerprint

Pseudomonas Infections
Hematologic Neoplasms
Pseudomonas aeruginosa
Transplants
Therapeutics
Mortality
Population
Transplant Recipients
tazobactam drug combination ceftolozane

Keywords

  • Ceftolozane-tazobactam
  • Hematologic malignancy
  • Hematopoietic-cell transplant
  • Pseudomonas aeruginosa

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

@article{19e878bab8e84fa8be1c0a5ef8b6f61d,
title = "Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients",
abstract = "Multidrug-resistant (MDR) Pseudomonas aeruginosa infection causes significant mortality among patients with hematologic malignancies and hematopoietic-cell transplant recipients. Ceftolozane-tazobactam (C-T) is a novel therapeutic option for MDR-P. aeruginosa infections but clinical experience in these patients is limited. We report favorable clinical outcomes and lack of limiting toxicities using C-T monotherapy to treat invasive MDR-P. aeruginosa infections in these patient populations.",
keywords = "Ceftolozane-tazobactam, Hematologic malignancy, Hematopoietic-cell transplant, Pseudomonas aeruginosa",
author = "Morgan Hakki and Lewis, {James S.}",
year = "2018",
month = "2",
day = "19",
doi = "10.1007/s15010-018-1125-5",
language = "English (US)",
pages = "1--4",
journal = "Infection",
issn = "0300-8126",
publisher = "Urban und Vogel",

}

TY - JOUR

T1 - Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients

AU - Hakki, Morgan

AU - Lewis, James S.

PY - 2018/2/19

Y1 - 2018/2/19

N2 - Multidrug-resistant (MDR) Pseudomonas aeruginosa infection causes significant mortality among patients with hematologic malignancies and hematopoietic-cell transplant recipients. Ceftolozane-tazobactam (C-T) is a novel therapeutic option for MDR-P. aeruginosa infections but clinical experience in these patients is limited. We report favorable clinical outcomes and lack of limiting toxicities using C-T monotherapy to treat invasive MDR-P. aeruginosa infections in these patient populations.

AB - Multidrug-resistant (MDR) Pseudomonas aeruginosa infection causes significant mortality among patients with hematologic malignancies and hematopoietic-cell transplant recipients. Ceftolozane-tazobactam (C-T) is a novel therapeutic option for MDR-P. aeruginosa infections but clinical experience in these patients is limited. We report favorable clinical outcomes and lack of limiting toxicities using C-T monotherapy to treat invasive MDR-P. aeruginosa infections in these patient populations.

KW - Ceftolozane-tazobactam

KW - Hematologic malignancy

KW - Hematopoietic-cell transplant

KW - Pseudomonas aeruginosa

UR - http://www.scopus.com/inward/record.url?scp=85042177282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042177282&partnerID=8YFLogxK

U2 - 10.1007/s15010-018-1125-5

DO - 10.1007/s15010-018-1125-5

M3 - Article

C2 - 29460229

AN - SCOPUS:85042177282

SP - 1

EP - 4

JO - Infection

JF - Infection

SN - 0300-8126

ER -